Back to top
more

CONMED (CNMD)

(Delayed Data from NYSE)

$73.43 USD

73.43
464,098

-1.33 (-1.78%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $73.43 0.00 (0.00%) 5:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

CONMED (CNMD) Earnings and Revenues Surpass Estimates in Q3

by Zacks Equity Research

CONMED's (CNMD) General Surgery unit witnessed revenue growth in Q3

Conmed (CNMD) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 252.00% and 16.07%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Conmed (CNMD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Avoid Betting on Integer Holdings Now

by Zacks Equity Research

Stiff competition in the MedTech space and weak segmental and operational performance weighs on Integer Holdings (ITGR).

Cerner Inks Deal to Simplify Advance Care Planning Procedure

by Zacks Equity Research

Cerner's (CERN) partners with Vynca to simplify advance care planning process, thereby enabling patients and clinicians to discuss and make critical end-of-life decisions.

Here's Why You Should Hold on to CONMED (CNMD) Stock for Now

by Zacks Equity Research

Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.

PDCO vs. CNMD: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PDCO vs. CNMD: Which Stock Is the Better Value Option?

CONMED (CNMD) Q2 Loss Narrower Than Expected, Revenues Top

by Zacks Equity Research

CONMED's (CNMD) core units - General Surgery and Orthopedic Surgery - witnessed revenue decline in Q2.

Conmed (CNMD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 93.14% and 22.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy CONMED (CNMD) Ahead of Earnings?

by Zacks Equity Research

CONMED (CNMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Conmed (CNMD) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Conmed (CNMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Earnings Preview: Conmed (CNMD) Q2 Earnings Expected to Decline

by Zacks Equity Research

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PDCO vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

PDCO vs. CNMD: Which Stock Is the Better Value Option?

PDCO vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

PDCO vs. CNMD: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.

Why Is Conmed (CNMD) Down 0.7% Since Last Earnings Report?

by Zacks Equity Research

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from broad product portfolio and persistent focus on R&D. However, forex remains a woe.

CONMED (CNMD) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

CONMED's (CNMD) first-quarter results gain from strong performance in General Surgery segment and expansion in margins.

Conmed (CNMD) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 15.91% and 2.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Conmed (CNMD) Q1 Earnings Expected to Decline

by Zacks Equity Research

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MMSI vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

MMSI vs. CNMD: Which Stock Is the Better Value Option?

Want To Retire Early? Learn the Intelligent Investing Secret - March 24, 2020

by Zacks Equity Research

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Here's Why You Should Hold on to CONMED (CNMD) Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.

Sreyoshi Mukherjee headshot

Coronavirus to Weigh on These 4 Medical Stocks' Q1 Show

by Sreyoshi Mukherjee

The coronavirus pandemic likely to disrupt the first-quarter performances of players in the MedTech space.

Why Is Conmed (CNMD) Down 6.5% Since Last Earnings Report?

by Zacks Equity Research

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.